Helsinki, Finland, 26 June 2025: Nordhealth AS (the "Company") hereby launches
an offer to purchase up to 300,000 of its own shares (the "Offering"). The
Offering will be carried out as a reversed book-building process where the
Company, through DNB Carnegie, will receive offers for desired volume(s) for
sale from the shareholders.
All shareholders in the Company are invited to sell shares in the Offering,
subject to the restrictions set out herein.
The Company has mandated DNB Carnegie as bookrunner for the Offering and
shareholders with interest to sell shares may contact DNB Carnegie via email
demand@dnb.no or by phone +47 24 16 90 20 before the end of the Application
Period (as defined below). Existing shareholders in the Company who would like
to participate in the Offering who are not registered as clients of the DNB
Carnegie must establish a client relationship before participating.
The Offering starts on 26 June 2025 at 09:00 CEST and will close no later than 2
July 2025 at 16:30 CEST (the "Application Period"). The final price offered by
the Company and the allocation of tendered shares are expected to be resolved by
the Company on or about 3 July 2025, the trade date is expected to be on or
about 3 July 2025, and the settlement date is expected to be on or about 7 July
2025. The settlement will be conducted on a normal delivery-versus-payment
basis. The Company reserves the right to extend the Application Period at its
own discretion. If the Application Period is extended, the other dates referred
to herein may be amended accordingly.
The shares will be purchased at a maximum of NOK 37 per share, which is above
the 60 days average volume weighted average price (VWAP) of the Company's
shares. The final purchase price will be identical for all selling shareholders.
The Company will in the event of receiving offers exceeding a total of 300,000
shares, allocate shares at its discretion in accordance with the best interest
of the Company, taking into account the prices and volumes offered, with equal
treatment of the shareholders as the primary objective.
The Company reserves the right to, at its own discretion, buy back fewer shares
or no shares at all, to terminate the Offering or make any amendments regarding
the volume or other terms of the Offering at any time until the time of
completion of the Offering.
Any shares acquired as part of the Offering will be used as consideration in
future acquisitions by the Company, as part of the employee share program, or
absent of this, be cancelled. Any shares purchased will be held in treasury
until used for any of the above purposes.
The Offering is launched, and repurchases are made, in accordance with the
authorisation granted to the board of directors by the Company's general meeting
held on 27 May 2025
For further information, please contact:
DNB Carnegie, demand@dnb.no, +47 24 16 90 20
Charles MacBain, CEO, charles.macbain@nordhealth.com, +44 75 3903 2200
Alexander Cram, CFO, alexander.cram@nordhealth.com, +32 470 69 30 20
About Nordhealth
Nordhealth is a publicly listed, fast-growing cloud-based healthcare SaaS
company on a mission to redefine digital healthcare. We build software that
empower veterinary and therapy professionals to provide the best possible care
experiences to their patients. Our products serve more than 60,000 veterinary
and therapy professionals across 13,000 clinics and hospitals located in over 30
countries.
Headquartered in Helsinki, Finland, Nordhealth has a solid footprint in the
Nordic region and a growing presence internationally, with 400 employees working
either remotely or from offices (collaboration hubs). Visit the company's
website at nordhealth.com (http://www.nordhealth.com).